Meeting
2022 ASCO Quality Care Symposium
The use of adjuvant chemotherapy in resected stage IB-IIIA non–small cell lung cancer (NSCLC) and comparison to the TriNetX database.
Authors
Ayesha Shameem
Charleston Area Medical Center, Charleston, WV
Ayesha Shameem, Steven Jubelirer, Frank Annie, Christine A. Welch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Guideline-Concordant Care Initiatives
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 29)
DOI
10.1200/JCO.2022.40.28_suppl.029
Abstract #
29
Poster Bd #
A27
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2015 ASCO Annual Meeting
Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.
First Author: Daniel Morgensztern
Poster
2013 ASCO Annual Meeting
Effect of age on impact of adjuvant chemotherapy for resected non-small cell lung cancer.
First Author: Apar Kishor Ganti
Poster
2012 ASCO Annual Meeting
Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p).
First Author: Jose Miguel Sanchez